Dissolvable medical device for drugs delivery
A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprises: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye and the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.
1 . A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprising: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye, wherein the polymeric film is circular and has a diameter 11 mm to 13 mm and a thickness 120 um-250 um, wherein the polymeric film comprising one or more mucoadhesive polymers, wherein the one or more mucoadhesive polymers are hydroxypropyl guar (HP guar), hyaluronic acid, or sodium hyaluronate or polyvinyl pyrrolidine or combinations thereof, wherein the polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye, wherein a pharmaceutically active agent is added in the polymeric film during manufacturing the polymeric film or onto the polymeric film after the polymeric film is placed on the outer surface of the eye or onto the polymeric film after manufacturing but before placing on the outer surface of the eye, wherein the dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye, wherein the pharmaceutically active agent is phenylephrine, wherein the dissolvable medical device comprising 0.0025% w/w to 2.5% w/w of phenylephrine, wherein comparing to apply the same amount of the phenylephrine to the cornea and wait for exact 10 minutes to measure, a pupil is dilated to a bigger size when the phenylephrine is delivered in the presence of the polymeric film than in the absence of the polymeric film.
2 . The dissolvable medical device of claim 1 , wherein the one or more
mucoadhesive polymers are present in an amount of at least 5% w/w HP guar, at least 5% w/w hyaluronic acid, at least 5% w/w polyvinyl pyrrolidine by dry weight of the polymeric film and a total amount of mucoadhesive polymers is equal to or less than 100% w/w by dry weight of the polymeric film.
3 . The dissolvable medical device of claim 1 further comprising a plasticizer or softener.
4 . The dissolvable medical device of claim 3 wherein the plasticizer or softener is selected from the group consisting of: polyethylene glycol (PEG), a PEG derivative, water, Vitamin E, and triethyl citrate.
5 . The dissolvable medical device claim 3 , wherein the plasticizer or softener is present in an amount of from about 2% to about 30% w/w, about 5% to about 25% w/w, about 5% to about 20% w/w, or about 5% to about 15% w/w of the polymeric film by dry weight of the polymeric film and a total amount of mucoadhesive polymers and the plasticizer or softener is equal to or less than 100% w/w by dry weight of the polymeric film.
6 . The dissolvable medical device of claim 4 , wherein the plasticizer or softener is PEG.
7 . The dissolvable medical device of claim 1 , wherein the insert is comprised of approximately 40% HP guar, approximately 10% PVP, approximately 40% sodium hyaluronate, and approximately 10% PEG.
8 . The dissolvable medical device of claim 1 , wherein the polymeric film is placed on the outer surface of the eye to delivery of pharmaceutically active agent to the eye before, during or post ophthalmic surgery.
9 . The dissolvable medical device of claim 8 , wherein ophthalmic surgery is selected from a group of glaucoma surgery, vision correction laser surgeries and cataract surgery.
10 . The dissolvable medical device of claim 9 , wherein vision correction laser surgeries is selected from a group of laser in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) and radial keratotomy (RK) for treating refraction defects.